Chronic Granulomatous Disease (CGD) Management Market

Chronic Granulomatous Disease (CGD) Management Market Size, Market Forecast and Outlook By FMI

Summary of the Chronic Granulomatous Disease (CGD) Management Market

• Demand and Growth Drivers
  • Gene therapy advancement is creating potential curative treatment options for CGD.
  • Diagnostic improvements are enabling faster and more accurate disease identification.
  • Stem cell transplant access expansion is providing curative options for more patients.
• Product and Segment View
  • X-linked CGD is expected to lead with 68.5% of category demand in 2026.
  • Genetic testing is expected to represent 42.7% of diagnostic demand.
  • Infection management is expected to account for 36.9% of treatment demand.
• Geography and Competitive Outlook
  • The USA (4.8%) is expected to lead growth through immunology infrastructure and gene therapy development.
  • South Korea (4.6%) maintains strong growth through diagnostic capabilities and trial participation.
  • Companies with gene therapy pipelines and rare disease expertise are expected to drive treatment innovation.
• Analyst Opinion
  • The CGD management market is evolving as gene therapy advances toward potential curative treatment.
  • Chronic prophylactic management remains the treatment foundation while curative approaches mature.
  • The market is benefiting from improving diagnostics and expanding stem cell transplant access.
  • Companies combining prophylactic treatment portfolios with gene therapy development are expected to capture emerging treatment value.

Key Takeaways, Market Size, and Forecast

• The chronic granulomatous disease (CGD) management market was valued at USD 1.44 billion in 2025.
• By 2036, the Chronic Granulomatous Disease (CGD) Management Market is expected to be worth USD 2.34 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 4.5%.
• The market is projected to create an incremental opportunity of USD 0.83 billion between 2026 and 2036.
• In 2026, x-linked chronic granulomatous disease is expected to account for 68.5% of the category segment, driven by predominant inheritance pattern accounting for the majority of diagnosed cases, established treatment protocols, and concentrated demand in specialized immunology centres.
• USA (4.8%) and South Korea (4.6%) are two of the fastest growing markets in the world.

Chronic Granulomatous Disease (CGD) Management Market Definition

The chronic granulomatous disease management market covers pharmaceutical, gene therapy, and supportive interventions used in managing CGD, a rare primary immunodeficiency characterized by defective phagocytic cells. Treatments include prophylactic antimicrobial therapy, interferon-gamma, hematopoietic stem cell transplantation, and emerging gene therapy approaches.

Chronic Granulomatous Disease (CGD) Management Market Inclusions

Market scope covers all commercially available CGD management products categorized by category (X-linked CGD, autosomal recessive CGD), diagnosis (genetic testing, dihydrorhodamine flow cytometry, nitroblue tetrazolium test, others), treatment (infection management, prophylactic therapy, stem cell transplantation, gene therapy, others), and end use (hospitals, specialty centres, homecare). Revenue coverage spans 2026 to 2036.

Chronic Granulomatous Disease (CGD) Management Market Exclusions

The scope does not include general immunology diagnostic panels, standard vaccination programs, or treatments for acquired immunodeficiency conditions.

Chronic Granulomatous Disease (CGD) Management Market Research Methodology

Primary Research: FMI analysts conducted interviews with immunologists, rare disease treatment specialists, and hospital pharmacy directors at immunodeficiency treatment centres.

Desk Research: Combined data from primary immunodeficiency registries, pharmaceutical prescription databases, and clinical trial registries.

Market Sizing and Forecasting: Bottom-up sizing across disease category, treatment modality, and end-use segments with regional immunodeficiency diagnosis rate curves.

Data Validation: Cross-checked quarterly against immunodeficiency registry data, pharmaceutical sales volumes, and gene therapy clinical trial updates.

Why is the Chronic Granulomatous Disease (CGD) Management Market Growing?

• Advancing gene therapy approaches for CGD are creating potential curative treatment options that could reduce lifelong dependence on prophylactic antimicrobial therapy and interferon-gamma treatment.
• Improving diagnostic capabilities including flow cytometry-based assays are increasing the speed and accuracy of CGD diagnosis, enabling earlier treatment initiation and prophylaxis.
• Expansion of hematopoietic stem cell transplantation access and improved conditioning regimens are providing curative options for an increasing proportion of CGD patients with suitable donors.

Demand for CGD management reflects the chronic nature of the immunodeficiency and the lifelong treatment requirements for infection prevention and management. CGD affects approximately 1 in 200,000 to 250,000 individuals, with X-linked inheritance accounting for approximately 65 to 70% of cases. Prophylactic antimicrobial therapy and interferon-gamma form the foundation of chronic management.

Adoption of X-linked CGD management leads at 68.5% of category demand, reflecting the predominance of this inheritance pattern in the diagnosed patient population. X-linked CGD typically presents in early childhood with severe and recurrent infections, driving early treatment initiation and sustained pharmaceutical management.

Pricing reflects the combination of chronic prophylactic antimicrobial costs, interferon-gamma therapy, and the substantial expense of stem cell transplantation or gene therapy for eligible patients. The orphan disease status supports premium pricing for specialized therapies while government-funded rare disease programs provide access support.

Market Segmentation Analysis

• X-Linked Chronic Granulomatous Disease accounts for 68.5% of the category segment.
• Genetic Testing represents 42.7% of the diagnosis segment.
• Infection Management leads the treatment segment with 36.9% share.

The chronic granulomatous disease (cgd) management market is segmented by category, diagnosis, treatment, and end use.

Insights into the X-Linked Chronic Granulomatous Disease Category Segment

X-linked CGD represents 68.5% of category demand due to its predominant inheritance pattern. Affecting males through mutations in the CYBB gene, X-linked CGD accounts for the majority of diagnosed cases and drives the largest proportion of chronic treatment demand.

Insights into the Genetic Testing Diagnosis Segment

Genetic testing represents 42.7% of diagnostic demand, reflecting its role as the definitive diagnostic method for confirming CGD and identifying the specific genetic mutation. Genetic confirmation supports treatment planning and family counseling.

Chronic Granulomatous Disease (CGD) Management Market Drivers, Restraints, and Opportunities

• Regulatory and structural demand drivers are creating sustained procurement patterns.
• Cost and access constraints create segmentation in adoption rates.
• Technology and product development are expanding the addressable market.

The chronic granulomatous disease (cgd) management market is shaped by regulatory, technology, and procurement dynamics.

Gene Therapy Pipeline Advancement

Demand is shaped by advancing gene therapy programs that target correction of the underlying genetic defects in CGD. Successful gene therapy could provide functional cure, reducing lifelong dependence on prophylactic therapy.

Diagnostic Capability Improvement

Growth reflects improving flow cytometry and genetic testing capabilities that enable faster and more accurate CGD diagnosis. Earlier diagnosis supports timely prophylaxis initiation and improved clinical outcomes.

Stem Cell Transplant Access Expansion

Adoption of hematopoietic stem cell transplantation is increasing as improved conditioning regimens and donor matching expand the proportion of CGD patients eligible for curative transplant.

Chronic Management Cost Burden

Lifelong prophylactic therapy creates sustained pharmaceutical expenditure. The cost burden drives interest in curative approaches including gene therapy and stem cell transplantation that could reduce long-term treatment costs.

Analysis of Chronic Granulomatous Disease (CGD) Management Market By Key Countries

Country	CAGR
USA	4.8%
South Korea	4.6%
EU	4.4%
UK	4.2%
Japan	4.1%

• USA leads with 4.8% CAGR.
• South Korea at 4.6% reflects expanding capabilities.
• EU (4.4%) and UK (4.2%) maintain steady growth.

The global chronic granulomatous disease (cgd) management market is expected to grow at 4.5% per year from 2026 to 2036.

Demand Outlook for Chronic Granulomatous Disease (CGD) Management Market in the United States

The USA is expected to grow at 4.8% through 2036, driven by advanced immunology infrastructure, gene therapy clinical trial activity, and comprehensive insurance coverage for rare immunodeficiency treatment.

• Immunology centres provide specialized CGD management.
• Gene therapy trials offer potential curative approaches.
• Insurance coverage supports chronic treatment costs.

Future Outlook for Chronic Granulomatous Disease (CGD) Management Market in South Korea

South Korea is expected to grow at 4.6% through 2036, supported by advanced genetic diagnostics, growing rare disease treatment infrastructure, and participation in multinational gene therapy trials.

• Genetic diagnostics support accurate CGD identification.
• Rare disease infrastructure investment expands treatment access.
• Clinical trial participation advances treatment options.

Opportunity Analysis of Chronic Granulomatous Disease (CGD) Management Market in the European Union

The EU is expected to grow at 4.5% through 2036, supported by EU rare disease treatment networks, immunology research investment, and cross-border specialist referral coordination.

• EU rare disease networks coordinate specialist treatment.
• Immunology research advances therapeutic options.
• Cross-border referral improves access to expertise.

Sales Analysis of Chronic Granulomatous Disease (CGD) Management Market in the United Kingdom

The UK is expected to grow at 4.3% through 2036, supported by NHS specialist commissioning, immunology research centres, and genomic medicine integration for primary immunodeficiency diagnosis.

• NHS specialist commissioning supports CGD treatment access.
• Immunology research centres drive protocol improvement.
• Genomic medicine improves diagnostic accuracy.

In-depth Analysis of Chronic Granulomatous Disease (CGD) Management Market in Japan

Japan is expected to grow at 4.4% through 2036, driven by established immunology centres, government rare disease programs, and advanced diagnostic infrastructure.

• Immunology centres provide comprehensive CGD care.
• Government programs support rare disease treatment costs.
• Diagnostic infrastructure enables early case identification.

Competitive Landscape and Strategic Positioning

• Horizon Therapeutics leads with an estimated 14.2% market share.
• The competitive landscape includes global and specialized players.
• Entry barriers include regulatory, relationship, and scale factors.

Horizon Therapeutics leads through its rare disease pharmaceutical portfolio with products supporting primary immunodeficiency management.

Takeda Pharmaceutical and Orchard Therapeutics maintain positions through rare disease treatment programs and gene therapy development relevant to CGD.

AVROBIO, Inc. and Rocket Pharmaceuticals represent emerging gene therapy positions with investigational programs targeting CGD correction.

Entry barriers include rare disease clinical expertise, small patient populations, gene therapy development costs, and specialized immunology distribution requirements.

Key Companies in the Chronic Granulomatous Disease (CGD) Management Market

Key global companies leading the chronic granulomatous disease (cgd) management market include:

• Horizon Therapeutics (USA), Takeda Pharmaceutical (Japan), and Orchard Therapeutics (UK) hold leading positions through rare disease portfolios and gene therapy programs.
• AVROBIO, Inc. (USA) and Rocket Pharmaceuticals (USA) compete on gene therapy development targeting CGD genetic correction.
• bluebird bio (USA), Mustang Bio (USA), and Genethon (France) represent additional gene therapy positions with primary immunodeficiency programs.

Competitive Benchmarking: Chronic Granulomatous Disease (CGD) Management Market

Company	Rare Disease Portfolio	Gene Therapy Pipeline	Patient Access Programs	Geographic Reach
Horizon Therapeutics	High	Low	Strong	N. America, Global
Takeda Pharmaceutical	High	Medium	Strong	Global
Orchard Therapeutics	Low	High	Moderate	Europe, N. America
AVROBIO, Inc.	Low	High	Low	N. America
Rocket Pharmaceuticals	Low	High	Low	N. America
Genethon	Low	High	Low	Europe

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Chronic Granulomatous Disease (CGD) Management Market

• In 2025, Orchard Therapeutics advanced its gene therapy program for X-linked CGD with expanded clinical trial enrollment across European treatment centres.
• In 2025, Rocket Pharmaceuticals reported positive interim data from its lentiviral gene therapy trial for X-linked CGD patients.

Key Players in the Chronic Granulomatous Disease (CGD) Management Market

Major Global Players

• Horizon Therapeutics
• Takeda Pharmaceutical
• Orchard Therapeutics
• AVROBIO, Inc.
• Rocket Pharmaceuticals
• Novartis AG
• Regeneron Pharmaceuticals

Emerging Players/Startups

• bluebird bio
• Mustang Bio
• Genethon
• Editas Medicine
• Sangamo Therapeutics

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 1.51 billion to USD 2.34 billion, at a CAGR of 4.5%
Market Definition	The chronic granulomatous disease management market covers pharmaceutical, gene therapy, and supportive interventions used in managing CGD, a rare primary immunodeficiency characterized by defective phagocytic cells. Treatments include prophylactic antimicrobial therapy, interferon-gamma, hematopoietic stem cell transplantation, and emerging gene therapy approaches.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled	Horizon Therapeutics, Takeda Pharmaceutical, Orchard Therapeutics, AVROBIO, Inc., Rocket Pharmaceuticals, Novartis AG, Regeneron Pharmaceuticals, CSL Behring, Gilead Sciences, Bluebird Bio
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Chronic Granulomatous Disease (CGD) Management Market Market Segmented by Category:

• X-Linked Chronic Granulomatous Disease
• Autosomal Recessive Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD) Management Market Market Segmented by Diagnosis:

• Genetic Testing
• Neutrophil Function Tests
• Prenatal Testing

Chronic Granulomatous Disease (CGD) Management Market Market Segmented by Treatment:

• Infection Management
• Trimethoprim
• Sulfamethoxazole
• Itraconazole
• Interferon-gamma
• Stem Cell Transplantation
• Others

Chronic Granulomatous Disease (CGD) Management Market Market Segmented by End Use:

• Hospitals
• Specialty Clinics
• Homecare Settings
• Research Institutes

Chronic Granulomatous Disease (CGD) Management Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. Jeffrey Modell Foundation. (2025). JMF Primary Immunodeficiency Registry Report. JMF.
• 2. European Society for Immunodeficiencies. (2024). ESID Clinical Practice Guidelines: CGD Management. ESID.
• 3. National Institutes of Health. (2025). NIH National Institute of Allergy and Infectious Diseases: CGD Research. NIAID.
• 4. USA Food and Drug Administration. (2025). FDA Gene Therapy Development for Primary Immunodeficiency. FDA.
• 5. World Health Organization. (2024). WHO Classification of Primary Immunodeficiency Disorders. WHO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the market size and revenue from 2026 to 2036.
• Segmentation by disease category, diagnosis, treatment, and end use.
• Regional and country-level insights across more than 30 markets.
• Gene therapy pipeline and clinical trial analysis.
• Competitive landscape assessment.
• Investment opportunity identification.
• Diagnostic technology and treatment protocol analysis.
• Data delivery in PDF and Excel formats.